Takeda’s Global Collaboration Agreement with Ovid Therapeutics Inc.

Sidley represented Takeda Pharmaceutical Company Limited in the formation of a global collaboration with Ovid Therapeutics Inc., a privately held biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases.

his collaboration will focus on the clinical development and commercialization of Takeda’s investigational new drug TAK-935, a novel, potent and highly selective CH24H inhibitor, in rare pediatric epilepsies. TAK-935 has successfully completed Phase 1 clinical development under Takeda’s leadership and will be moving into Phase 1b/2a clinical studies, in rare epileptic encephalopathies, where patients continue to suffer from significant unmet medical needs.

The Sidley team was led by Jeffrey Rothstein (Picture) and included Scott Williams and Rachelle Soderstrom.

Involved fees earner: Jeffrey Rothstein – Sidley Austin LLP; Rachelle Soderstrom – Sidley Austin LLP; Scott Williams – Sidley Austin LLP;

Law Firms: Sidley Austin LLP;

Clients: Takeda;


Author: Ambrogio Visconti